Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

Pharmacogenomics Journal

Volumn 13, Issue 2, 2013, Pages 173-180

  Pohl, A ^a   El Khoueiry, A ^a   Yang, D ^b   Zhang, W ^a   Lurje, G ^a   Ning, Y ^a   Winder, T ^a   Hu Lieskoven, S ^a   Iqbal, S ^a   Danenberg, K D ^c   Kahn, M ^a   Teo, J L ^a   Shriki, J ^b   Stebbing, J ^d   Lenz, H J ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Response Genetics   (United States)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

bevacizumab; CD133; colorectal cancer; molecular markers; predictive markers; prominin 1

Indexed keywords

BEVACIZUMAB; CD133 ANTIGEN; FLUOROURACIL; GENOMIC DNA; MESSENGER RNA; OXALIPLATIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NUCLEOTIDE SEQUENCE; ONCOGENE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PEPTIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875428597     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.61     Document Type: Article

References (29)

1. Ferrandina G, Petrillo M, Bonanno G, Scambia G. Targeting CD133 antigen in cancer. Expert Opin Ther Targets 2009; 13: 823-837.
2. Pohl A, Lurje G, Kahn M, Lenz HJ. Stem cells in colon cancer. Clin Colorectal Cancer 2008; 7: 92-98.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
4. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951.
5. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542-2556.
6. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
7. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115.
8. Yu SC, Ping YF, Yi L, Zhou ZH, Chen JH, Yao XH et al. Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett 2008; 265: 124-134.
9. Haraguchi N, Ohkuma M, Sakashita H, Matsuzaki S, Tanaka F, Mimori K et al. CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 2008; 15: 2927-2933.
10. Puglisi MA, Sgambato A, Saulnier N, Rafanelli F, Barba M, Boninsegna A et al. Isolation and characterization of CD133+ cell population within human primary and metastatic colon cancer. Eur Rev Med Pharmacol Sci 2009; 13(Suppl 1): 55-62.
11. Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009; 457: 603-607.
12. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest 2008; 118: 2111-2120.
13. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468: 829-833.
14. Elkhafif N, El Baz H, Hammam O, Hassan S, Salah F, Mansour W et al. CD133(+) human umbilical cord blood stem cells enhance angiogenesis in experimental chronic hepatic fibrosis. APMIS 2011; 119: 66-75.
15. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000; 4: 135-142.
16. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res, 14, 7884-7895.
17. Halpern J. Maximally selected X2 statistics for small samples. Biometrics 1982; 38: 1017-1023.
18. Siegmund R. Maximally selected X2 statistics. Biometrics 1982; 38: 1011-1016.
19. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15: 3223-3229.
20. Schneider S, Park DJ, Yang D, El-Khoueiry A, Sherrod A, Groshen S et al. Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenet Genomics 2006; 16: 555-563.
21. Gonen M. Concordance probability and discriminatory power in proportional hazards regression. Biometrika 2005; 92: 965-970.
22. Berry G, Kitchin RM, Mock PA. A comparison of two simple hazard ratio estimators based on the log-rank test. Stat Med 1991; 10: 749-755.
23. Molinaro AM, Simon R, Pfeiffer RM. Prediction error estimation: a comparison of resampling methods. Bioinformatics 2005; 21: 3301-3307.
24. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 2000; 19: 1141-1164.
25. Barcelos LS, Duplaa C, Krankel N, Graiani G, Invernici G, Katare R et al. Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling. Circ Res 2009; 104: 1095-1102.
26. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000; 95: 3106-3112.
27. Senegaglia AC, Brofman PR, Aita CA, Dallagiovanna B, Rebelatto CL, Hansen P et al. In vitro formation of capillary tubules from human umbilical cord blood cells with perspectives for therapeutic application. Rev Bras Cir Cardiovasc 2008; 23: 467-473.
28. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
29. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147.